Anti-angiogenic treatment strategies for malignant brain tumors.

作者: Matthias Kirsch , Gabriele Schackert , Peter McL. Black

DOI: 10.1023/A:1006487412567

关键词: Combined Modality TherapyAngiogenesisBrain tumorAdjuvant therapyVascular endothelial growth factorGliomaNeovascularizationPathologyCancer researchCancerMedicine

摘要: The use of angiogenesis inhibitors may offer novel strategies in brain tumor therapy. In contrast to traditional cancer treatments that attack cells directly, target at the formation tumor-feeding blood vessels provide continuous supply nutrients and oxygen. With respect therapy, display unique features are unknown conventional chemotherapeutic agents. most important independence blood-brain barrier, cell type specificity, reduced resistance. Malignant tumors, especially malignant gliomas, among vascularized tumors known. Despite multimodal therapeutic approaches, prognosis remains dismal. Thus, be highly effective drugs against these tumors. a clinical setting, they could applied treatment multiple or postsurgically as an adjuvant therapy prevent recurrence. This article provides overview current anti-angiogenic with emphasis on substances already trials candidate for trials. cellular molecular basis is reviewed.

参考文章(155)
Vicki Brower, Tumor angiogenesis : new drugs on the block Nature Biotechnology. ,vol. 17, pp. 963- 968 ,(1999) , 10.1038/13654
Randi D Oehring, Melitta Miletic, Markus M Valter, Torsten Pietsch, Jürgen Neumann, Rolf Fimmers, Uwe Schlegel, None, Vascular endothelial growth factor (VEGF) in astrocytic gliomas--a prognostic factor? Journal of Neuro-oncology. ,vol. 45, pp. 117- 125 ,(1999) , 10.1023/A:1006333005563
J. Partanen, D. J. Dumont, Functions of Tie1 and Tie2 Receptor Tyrosine Kinases in Vascular Development Current Topics in Microbiology and Immunology. ,vol. 237, pp. 159- 172 ,(1999) , 10.1007/978-3-642-59953-8_8
André Luís Moreira, David Raul Friedlander, Bronya Shif, Gilla Kaplan, David Zagzag, Thalidomide and a thalidomide analogue inhibit endothelial cell proliferation in vitro. Journal of Neuro-oncology. ,vol. 43, pp. 109- 114 ,(1999) , 10.1023/A:1006202700039
H.J.J.A. Bernsen, P.F.J.W. Rijken, J.P.W. Peters, J.H. Bakker, R.H. Boerman, P. Wesseling, A.J. van der Kogel, Suramin treatment of human glioma xenografts; effects on tumor vasculature and oxygenation status. Journal of Neuro-oncology. ,vol. 44, pp. 129- 136 ,(1999) , 10.1023/A:1006363215260
Sven Wagner, Carola Stegen, Hakim Bouterfa, Claudia Huettner, Siglinde Kerkau, Wolfgang Roggendorf, Klaus Roosen, Joerg-Christian Tonn, Expression of matrix metalloproteinases in human glioma cell lines in the presence of IL-10. Journal of Neuro-oncology. ,vol. 40, pp. 113- 122 ,(1998) , 10.1023/A:1006146405880
William A. Frazier, Vivian S. Zabrenetzky, Patricia S. Steeg, David D. Roberts, Kenneth VanHoutte, Debra L. Weinstat-Saslow, Transfection of Thrombospondin 1 Complementary DNA into a Human Breast Carcinoma Cell Line Reduces Primary Tumor Growth, Metastatic Potential, and Angiogenesis Cancer Research. ,vol. 54, pp. 6504- 6511 ,(1994)
Georg Breier, Marcia Machein, Annette Damert, Masaki Q. Fujita, Masaki Q. Fujita, Werner Risau, Karl H. Plate, Douglas Hanahan, Up-Regulation of Vascular Endothelial Growth Factor Expression in a Rat Glioma Is Conferred by Two Distinct Hypoxia-driven Mechanisms Cancer Research. ,vol. 57, pp. 3860- 3864 ,(1997)
G. Breier, B. Millauer, A. Ullrich, W. Risau, K. H. Plate, Up-Regulation of Vascular Endothelial Growth Factor and Its Cognate Receptors in a Rat Glioma Model of Tumor Angiogenesis Cancer Research. ,vol. 53, pp. 5822- 5827 ,(1993)